past
year
dna
vaccin
gone
scientif
curios
one
dynam
research
field
may
offer
new
altern
control
parasit
diseas
leishmaniasi
chaga
diseas
review
advanc
challeng
develop
dna
vaccin
diseas
mani
studi
valid
concept
use
dna
vaccin
protect
therapi
protozoan
parasit
varieti
mous
model
challeng
translat
achiev
model
veterinari
human
vaccin
compar
efficaci
also
genomemin
new
antigen
discoveri
strategi
may
provid
new
tool
ration
search
novel
vaccin
candid
spite
success
vaccin
public
health
still
numer
pathogen
particular
protozoan
parasit
plasmodium
falciparum
trypanosoma
sp
leishmania
sp
still
effect
vaccin
howev
discoveri
direct
inject
plasmid
dna
encod
foreign
protein
could
lead
endogen
protein
biosynthesi
specif
immun
respons
open
new
perspect
vaccin
develop
year
later
dna
vaccin
gone
scientif
curios
one
dynam
field
research
may
offer
new
altern
control
infecti
diseas
inde
first
two
dna
vaccin
licenc
recent
year
protect
hors
west
nile
viru
salmon
infecti
hematopoiet
necrosi
viru
confirm
use
biotechnolog
review
advanc
challeng
develop
dna
vaccin
two
wellstudi
protozoan
parasit
leishmania
sp
trypanosoma
cruzi
belong
trypanosomatida
famili
rank
among
three
major
protozoan
parasit
affect
human
leishmaniasi
complex
diseas
caus
least
speci
parasit
leishmania
genu
transmit
human
hematophag
sandfli
estim
million
case
major
public
health
impact
sever
region
particular
india
sudan
brazil
clinic
manifest
rang
selfheal
cutan
lesion
fatal
viscer
form
varieti
attribut
part
respect
parasit
speci
present
specif
relationship
host
divers
mechan
pathogenesi
repres
addit
difficulti
develop
treatment
vaccin
hand
cruzi
agent
chaga
diseas
present
southern
argentina
southern
usa
estim
million
person
infect
america
close
million
peopl
risk
infect
short
benign
acut
phase
week
long
sever
year
asymtomat
phase
infect
patient
develop
chronic
chagas
cardiomyopathi
eventuali
die
heart
failur
current
chemotherapi
reli
nitrofuran
nifurtimox
nitroimidazol
benznidazol
howev
use
drug
limit
reduc
efficaci
mostli
earli
stage
infect
seriou
side
effect
emerg
drugresist
strain
parasit
new
treatment
slow
develop
dna
vaccin
induc
complet
immun
respons
encod
antigen
exact
mechan
involv
proccess
still
poorli
understood
particularli
type
effector
memori
cell
activ
aspect
review
detail
elsewher
apart
immunogen
efficaci
discuss
sever
featur
dna
vaccin
make
advantag
tropic
diseas
first
extrem
safe
contain
pathogen
organ
may
revert
virul
major
concern
genom
integr
plasmid
dna
also
extens
studi
safeti
studi
found
rather
unlik
addit
safeti
issu
antidna
antibodi
autoimmun
also
address
grow
number
preclin
clinic
studi
confirm
high
safeti
vaccin
respect
manufactur
storag
distribut
also
present
major
benefit
product
process
dna
vaccin
case
type
biolog
vaccin
specif
protocol
develop
make
product
easi
cost
like
go
type
vaccin
becom
mainstream
futur
technolog
improv
implement
also
plasmid
dna
stabl
molecul
special
compar
recombin
live
attenu
vaccin
would
greatli
facilit
storag
distribut
dna
vaccin
tropic
set
limit
health
infrastructur
huge
cost
associ
cold
chain
may
offset
administr
also
easi
simpl
im
id
inject
suffici
multipl
plasmid
combin
elabor
multival
vaccin
overal
dna
vaccin
may
thu
repres
ideal
afford
altern
diseas
control
explain
part
grow
interest
develop
control
tropic
parasit
diseas
malaria
leishmaniasi
chaga
diseas
mention
leishmaniasi
caus
least
speci
parasit
divers
relationship
host
mechan
pathogenesi
earli
studi
crossprotect
leishmania
speci
clearli
show
complex
problem
infect
one
speci
protect
subsequ
infect
anoth
speci
depend
speci
order
infect
vaccin
studi
thu
focus
homolog
protect
although
singl
vaccin
abl
protect
pathogen
speci
would
ideal
correl
protect
extens
studi
case
l
major
contribut
consider
develop
paradigm
thu
gener
agreement
immun
respons
character
high
low
product
lead
control
l
major
infect
immun
respons
antibodi
may
exacerbatori
role
may
also
contribut
cell
respons
produc
cell
seem
contribut
protect
immun
induct
product
macrophag
central
parasit
elimi
assum
long
time
paradigm
appli
leishmania
speci
becom
clear
recent
year
speci
distinct
relationship
host
differ
mechan
pathogenesi
possibl
differ
correl
protect
nonetheless
product
seem
gener
requir
although
necessarili
suffici
protect
leishmania
speci
earliest
dna
vaccin
experi
leishmania
use
l
major
antigen
extens
use
recombin
peptid
vaccin
immun
plasmid
encod
abl
induc
cytokin
profil
signific
reduct
lesion
size
challeng
immun
mice
l
major
subsequ
studi
investig
dna
vaccin
encod
larg
varieti
leishmania
protein
tabl
show
mani
differ
dna
vaccin
abl
induc
immun
respons
confer
variabl
degre
protect
assess
reduct
skin
lesion
size
andor
parasit
burden
mous
model
howev
given
larg
varieti
experiment
model
design
difficult
compar
effect
differ
vaccin
induc
protect
immun
respons
nonetheless
clear
studi
compar
differ
dna
vaccin
natur
antigen
encod
vaccin
key
paramet
efficaci
also
studi
provid
interest
comparison
antigen
administ
recombin
protein
dna
vaccin
show
latter
overal
effect
recombin
protein
counterpart
inde
dna
vaccin
abl
induc
stronger
bia
immun
respons
longerlast
immun
andor
better
protect
diseas
progress
studi
use
rather
artifici
infecti
challeng
base
inject
via
nonnatur
rout
high
parasit
dose
experiment
system
critic
author
superior
efficaci
dna
vaccin
also
observ
use
lowdos
intraderm
challeng
ear
propos
close
mimick
natur
infect
studi
dna
protein
vaccin
abl
induc
similar
level
shortterm
week
postvaccin
protect
infect
l
major
dna
vaccin
abl
induc
longterm
week
postvaccin
protect
result
thu
confirm
strong
potenti
dna
vaccin
leishmania
also
indic
case
partial
protect
achiev
primeboost
immun
protocol
test
variou
antigen
increas
vaccin
potenc
tabl
base
prime
immun
respons
dna
vaccin
boost
correspond
recombin
vaccin
base
recombin
viru
protein
tabl
studi
immun
protocol
result
increas
immunogen
vaccin
better
protect
level
other
dna
remain
best
formul
optimum
efficaci
nonetheless
major
drawback
vaccin
formul
remain
complex
may
limit
practic
use
altern
way
broaden
vaccin
immunogen
increas
efficaci
use
combin
plasmid
encod
variou
antigen
exampl
cystein
proteinas
cp
b
dna
vaccin
protect
use
individu
immun
combin
plasmid
induc
longterm
protect
immun
altern
gene
fusion
also
success
use
achiev
express
antigen
fusion
protein
singl
plasmid
construct
overal
express
sever
antigen
mostli
result
increas
efficaci
also
depend
antigen
combin
author
thu
argu
success
leishmania
vaccin
like
base
multipl
antigen
immun
larg
number
plasmid
also
basi
express
librari
immun
power
laborintens
strategi
vaccin
discoveri
use
leishmania
immun
mice
l
major
genom
express
librari
fraction
abl
induc
signific
protect
author
pursu
librari
fraction
anoth
studi
identif
protect
librari
subset
l
donovani
amastigot
cdna
librari
success
fraction
smaller
protect
librari
lead
identif
novel
protect
antigen
interestingli
antigen
identifi
would
predict
good
vaccin
candid
inde
surfac
secret
protein
neither
stagespecif
intracellular
conserv
histon
ribosom
protein
vaccin
discoveri
also
next
logic
step
follow
recent
complet
l
major
genom
sequenc
one
approach
random
screen
gene
upregul
amastigot
test
dna
vaccin
allow
identif
novel
protect
exacerb
antigen
function
cellular
local
would
poor
predictor
protect
efficaci
antigen
predict
local
surfac
share
similar
ribosom
protein
cytoskeleton
metabol
enzym
thu
becom
increasingli
clear
littl
rational
limit
leishmania
vaccin
discoveri
search
surfac
secret
antigen
rather
new
criteria
need
consid
ration
identif
vaccin
candid
strategi
base
random
screen
appli
larg
genom
leishmania
annot
gene
addit
advantag
dna
vaccin
potenti
therapeut
vaccin
aim
reinforc
redirect
immun
respons
infect
host
control
diseas
progress
major
advantag
strategi
addit
efficaci
reli
short
treatment
regimen
thu
attract
altern
chemotherapi
particularli
case
leishmania
chemotherapeut
option
thu
administr
littl
two
dose
dna
vaccin
encod
control
ongo
infect
l
major
mice
therapeut
effect
due
shift
immun
respons
toward
immun
respons
similarli
dna
vaccin
encod
l
donovani
nucleosid
hydrolas
therapeut
activ
murin
viscer
leishmaniasi
caus
l
chagasi
simplic
treatment
make
advantag
compar
chemotherapi
addit
fact
dna
vaccin
effect
prophylaxi
therapi
leishmania
infect
thu
promis
would
provid
versatil
tool
control
parasit
mention
ad
challeng
leishmania
vaccin
develop
larg
number
speci
well
variabl
within
speci
inde
studi
polymorph
lead
antigen
quickli
reveal
polymorph
polymorph
import
implic
vaccin
develop
may
limit
efficaci
variant
strain
parasit
novel
escap
mutant
thu
restrict
vaccin
protect
singl
speci
antigen
polymorph
multipl
strain
speci
thu
becom
major
issu
mani
vaccin
develop
studi
case
leishmania
dna
vaccin
test
multipl
speci
lack
antigen
initi
identifi
l
major
found
conserv
leishmania
speci
protect
mice
l
major
l
amazonensi
l
mexicana
l
donovani
l
chagasi
hand
l
amazonensi
nucleas
protein
protect
l
amazonensi
l
major
crossprotect
requir
differ
formul
adjuv
resp
studi
antigen
one
speci
use
induc
protect
anoth
speci
extent
crossprotect
variou
speci
investig
recent
singl
formul
l
donovani
dna
vaccin
found
induc
good
protect
l
chagasi
l
mexicana
suggest
dna
vaccin
may
abl
provid
broad
protect
variou
leishmania
speci
importantli
dna
vaccin
yet
test
l
braziliensi
spite
speci
respons
case
cutan
leishmaniasi
south
america
dna
vaccin
base
leishmania
antigen
altern
approach
use
antigen
deriv
sandfli
saliva
inde
shown
sandfli
saliva
exacerb
leishmania
infect
preexposur
mice
saliva
compon
may
suffici
induc
protect
infect
thu
number
salivari
antigen
test
vaccin
leishmania
maxadilan
potent
vasodil
sandfli
saliva
found
respons
exacerbatori
effect
whole
saliva
leishmania
infect
immun
antigen
recombin
vaccin
protect
mice
l
major
infect
salivari
compon
phlebotomu
papatasi
test
dna
vaccin
found
protect
mice
l
major
vaccin
induc
humor
dth
respons
protect
seem
mostli
account
latter
bcell
defici
mice
remain
protect
thu
character
sandfli
salivari
protein
may
lead
identif
new
vaccin
candid
howev
leishmania
antigen
salivari
protein
polymorph
remain
import
issu
may
limit
use
antigen
vaccin
candid
base
success
mani
dna
vaccin
studi
mice
vaccin
candid
test
addit
anim
model
possibl
relev
develop
veterinari
human
vaccin
tabl
antigen
test
dna
vaccin
hamster
highli
suscept
anim
model
test
protein
dna
dnaprotein
immun
protect
level
l
mexicana
vari
greatli
depend
vaccin
formul
rout
immun
sex
anim
also
contrari
mous
studi
protein
vaccin
seem
protect
dna
vaccin
howev
mous
studi
heterolog
primeboost
vaccin
dna
protein
seem
better
dna
anoth
dna
vaccin
encod
found
immunogen
hamster
decreas
parasitemia
infect
l
infantum
assess
diseas
perform
immun
dna
induc
mix
respons
abl
protect
hamster
viscer
leishmaniasi
caus
l
donovani
dog
sever
protein
vaccin
test
purifi
protein
vaccin
licenc
veterinari
use
dna
vaccin
studi
perform
heterolog
primeboost
strategi
use
cpa
cpb
dna
protein
report
immunogen
protect
studi
limit
power
given
reduc
number
anim
anoth
studi
dog
immun
mixtur
dna
vaccin
encod
differ
antigen
previous
test
mous
model
immun
induc
good
immun
respons
high
product
howev
evalu
protect
limit
acut
vitro
assay
studi
requir
assess
potenti
vaccin
dog
spite
limit
studi
clearli
show
sever
dna
vaccin
induc
potent
immun
respons
nonmurin
anim
model
like
good
level
protect
achiev
well
provid
correct
antigen
vaccin
formul
use
vaccin
develop
chaga
diseas
dramat
limit
extens
debat
mechan
involv
patholog
inde
studi
suggest
tissu
damag
associ
presenc
replic
intracellular
amastigot
other
propos
autoimmun
induc
parasit
antigen
mimick
host
protein
respons
thu
unclear
immun
respons
need
inhibit
reduc
autoimmun
stimul
elimin
parasit
accept
presenc
parasit
cardiac
tissu
necessari
initi
maintain
inflammatori
respons
therapeut
treatment
vaccin
aim
elimin
cruzi
would
limit
prevent
progress
toward
chronic
chagas
cardiomyopathi
grow
consensu
protect
cruzi
reli
immun
respons
activ
cytotox
cell
first
dna
vaccin
test
cruzi
encod
antigen
well
character
transsialidas
famili
protein
member
famili
make
one
largest
protein
famili
parasit
abund
surfac
protein
sever
studi
use
differ
member
famili
ts
tabl
immun
ts
found
induc
signific
antibodi
titer
abl
inhibit
transsialidas
enzym
activ
strong
dth
lymphoprolif
respons
immun
respons
protect
determin
increas
surviv
decreas
parasitemia
immun
dna
found
induc
specif
ctl
respons
also
lead
lower
parasitemia
increas
surviv
balbc
mice
leishmania
vaccin
studi
author
address
question
compar
protein
dna
vaccin
encod
antigen
asn
mice
immun
recombin
ts
induc
higher
antibodi
titer
ts
dna
compar
decreas
parasitemia
howev
dna
vaccin
unabl
increas
surviv
author
attribut
strain
mice
use
sinc
dna
vaccin
protect
balbc
mice
hand
immun
recombin
crp
crp
dna
induc
compar
immun
respons
dna
vaccin
protect
infect
number
studi
show
dna
vaccin
encod
variou
antigen
could
induc
signific
protect
cruzi
infect
evidenc
decreas
parasitemia
improv
surviv
vaccin
mice
tabl
addit
studi
also
present
evid
reduct
cardiac
tissu
damag
inflamm
histopatholog
level
furthermor
cell
analysi
confirm
protect
reli
cell
recent
studi
show
cell
rapidli
activ
follow
infect
mice
immun
dna
vaccin
dna
vaccin
base
defin
cell
epitop
ts
antigen
also
test
found
journal
biomedicin
biotechnolog
im
intramuscular
ctl
cytolyt
activ
protect
littl
protect
fair
protect
good
protect
cell
epitop
necessari
suffici
induc
protect
immun
respons
taken
togeth
data
clearli
demonstr
vaccin
result
increas
patholog
initi
fear
allow
least
partial
control
diseas
progress
thu
confirm
central
role
parasit
persist
chaga
diseas
pathogenesi
open
way
assess
dna
vaccin
cruzi
howev
note
mani
antigen
test
belong
transsialidas
famili
protein
still
littl
divers
term
antigen
test
vaccin
cruzi
tabl
protect
induc
singl
antigen
dna
vaccin
remain
partial
number
studi
evalu
strategi
increas
vaccin
efficaci
includ
use
cytokinechemokin
encod
plasmid
potenti
immun
respons
induc
vaccin
two
studi
molecul
gmcsf
gener
abl
potenti
protect
tabl
altern
mixtur
plasmid
encod
distinct
antigen
use
immun
mention
leishmania
vaccin
exampl
immun
mice
plasmid
encod
ts
protein
result
specif
immun
respons
antigen
increas
protect
infect
hand
immun
mixtur
dna
vaccin
encod
protein
mucin
famili
result
poorli
protect
mixtur
protein
ts
famili
protect
much
singl
antigen
vaccin
encod
tslike
antigen
similarli
mixtur
dna
vaccin
encod
similar
protect
activ
alon
lack
efficaci
multival
vaccin
may
attribut
presenc
share
immunodomin
epitop
sinc
signific
sequenc
similar
may
result
broader
immun
repons
heterolog
primeboost
approach
also
evalu
immun
combin
dna
recombin
ts
found
enhanc
immun
respons
protect
significantli
differ
obtain
dna
alon
taken
togeth
studi
suggest
addit
strategi
need
investig
potenti
dna
vaccin
efficaci
cruzi
therapeut
administr
dna
vaccin
control
ongo
infect
cruzi
may
repres
addit
eric
dumonteil
altern
chaga
diseas
control
concept
demonstr
mice
acut
chronic
infect
case
administr
two
dose
dna
vaccin
encod
antigen
suffici
limit
diseas
progress
treat
mice
present
increas
surviv
reduc
cardiac
tissu
damag
assess
histopatholog
analysi
compar
studi
differ
dna
vaccin
identifi
antigen
anoth
therapeut
vaccin
candid
dna
vaccin
encod
antigen
ts
famili
previous
found
protect
signifiacnt
therapeut
effect
found
therapeut
vaccin
rapidli
induc
spleen
cell
prolifer
includ
cell
effect
cardiac
tissu
inflamm
parasit
burden
take
longer
detect
importantli
studi
therapeut
vaccin
cruzi
infect
mice
result
increas
inflammatori
reaction
heart
confirm
safe
stimul
immun
respons
cruzi
infect
mice
attack
parasit
lead
reduct
patholog
studi
thu
open
attract
perspect
control
cruzi
infect
studi
efficaci
dna
vaccin
encod
antigen
immun
mechan
underli
therapeut
effect
provid
clue
optim
strategi
vaccin
natur
antigen
use
remain
key
factor
vaccin
efficaci
still
littl
varieti
term
antigen
evalu
dna
vaccin
candid
cruzi
thu
number
studi
aim
identifi
novel
antigen
variou
strategi
classic
approach
screen
cdna
librari
use
antibodi
screen
amastigot
librari
allow
identif
novel
antigen
two
previous
character
one
dna
vaccin
encod
antigen
induc
variabl
level
protect
best
one
lyt
altern
expressionlibrari
immun
describ
leishmania
also
test
cruzi
found
immunogen
attempt
fraction
librari
identifi
protect
antigen
like
reason
strategi
may
laborintens
larg
genomeslibrari
use
may
limit
pathogen
small
genom
avail
cruzi
genom
sequenc
also
open
new
possibl
antigen
discoveri
one
first
studi
use
resourc
combin
bioinformat
analysi
use
identifi
gpianchor
secret
protein
identifi
clone
immunogen
dna
vaccin
studi
may
confirm
use
new
vaccin
protect
cruzi
infect
nonetheless
discuss
leishmania
rational
limit
antigen
search
surfac
protein
may
total
relev
addit
strategi
also
use
includ
unbiais
genomewid
survey
antigen
discoveri
detail
review
consider
advanc
dna
vaccin
leishmania
cruzi
recent
year
taken
togeth
studi
clearli
valid
concept
use
dna
vaccin
protect
therapi
protozoan
parasit
varieti
mous
model
steril
immun
seem
irrealist
goal
either
leishmania
cruzi
reduct
diseas
sever
develop
patholog
seem
clearli
within
reach
dna
vaccin
nonetheless
relev
mous
model
develop
veterinari
human
vaccin
parasit
challeng
author
dna
vaccin
studi
nonmurin
model
leishmaniasi
suggest
extrapol
may
feasibl
certainli
complet
addit
advanc
preclin
studi
dna
vaccin
candid
nonmurin
anim
model
rat
hamster
dog
monkey
thu
warrant
next
year
explor
immunolog
efficaci
dna
vaccin
parasit
alreadi
observ
studi
pathogen
lead
challeng
achiev
speci
immunogen
compar
level
protect
efficaci
obtain
murin
model
howev
advanc
adjuv
dna
vaccin
formul
deliveri
system
like
contribut
result
anoth
major
issu
antigen
discoveri
number
dna
vacin
test
far
leishmania
cruzi
shown
promis
still
unsur
best
possibl
antigen
particularli
sinc
parasit
rel
larg
genom
limit
varieti
antigen
test
avail
genom
sequenc
parasit
without
doubt
key
resourc
genomewid
screen
new
protect
antigen
key
lesson
initi
studi
review
togeth
similar
antigen
discoveri
studi
seem
cellular
local
protein
function
poor
predictor
antigen
protect
efficaci
protein
altern
criteria
thu
use
potent
vaccin
candid
miss
import
develop
genomemin
bioinformat
tool
provid
new
tool
ration
search
vaccin
candid
conclud
dna
vaccin
repres
promis
approach
control
leishmania
sp
cruzi
vaccin
would
major
impact
develop
endem
countri
thu
question
seem
dna
vaccin
control
parasit
sinc
mani
studi
clearli
show
case
translat
achiev
mous
model
veterinari
human
vaccin
compar
efficaci
work
fund
grant
consejo
nacion
de
ciencia
conacyt
